Valuation BIOSTAXPAR

Stocks

Market Closed - OTC Markets Other stock markets 13:27:45 2025-09-22 EDT			5-day change	1st Jan Change
0.000100 ^USD	-50.00%		-.--%	-

03-27	Callan Jmb Inc. Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2B/3 Advancement in A Collaboration Led by Difgen Pharmaceuticals, Aveva Drug Delivery Systems, Biostax Corp and Sgp Holdings	CI
03-25	DifGen Pharmaceuticals and Aveva Drug Delivery Systems Form Strategic Platform Collaboration with Biostax Corp D/B/A Attune Biotech, SGP Holdings, and Callan JMB	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2018	2019	2020	2021	2022	2023
Market Cap ¹	1.954	2.974	6.835	1.441	49.83	6.11
Change	-	52.18%	129.81%	-78.92%	3,358.09%	-87.74%
Enterprise Value (EV) ¹	7.136	8.515	9.67	2.088	50.37	7.264
Change	-	19.31%	13.57%	-78.41%	2,312.7%	-85.58%
P/E	-0.24x	-0.88x	4.35x	7.87x	-6x	-3.65x
PBR	-0.17x	-0.22x	-0.59x	-0.18x	-19.8x	-1.6x
PEG	-	0x	-0x	-0.1x	0x	0x
Capitalization / Revenue	17.2x	-	-	-	-	-
EV / Revenue	62.9x	-	-	-	-	-
EV / EBITDA	-1.75x	-3x	-10.9x	-2.83x	-	-5.08x
EV / EBIT	-1.75x	-3x	-10.9x	-2.83x	-43.3x	-4.89x
EV / FCF	-3.3x	84.8x	-83x	-1x	-8.65x	-20.3x
FCF Yield	-30.3%	1.18%	-1.2%	-100%	-11.6%	-4.93%
Dividend per Share ²	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-
EPS ²	-19.03	-7.423	3.334	0.38	-0.1	-0.02
Distribution rate	-	-	-	-	-	-
Net sales ¹	0.1135	-	-	-	-	-
EBITDA ¹	-4.083	-2.836	-0.8864	-0.7375	-	-1.431
EBIT ¹	-4.085	-2.838	-0.887	-0.7382	-1.163	-1.485
Net income ¹	-8.175	-3.397	1.589	3.586	-3.536	-1.651
Net Debt ¹	5.182	5.54	2.835	0.647	0.546	1.154
Reference price ²	4.500000	6.500000	14.510000	2.990000	0.600000	0.073035
Nbr of stocks (in thousands)	434	458	471	482	83,046	83,658
Announcement Date	4/16/19	5/14/20	4/15/21	3/18/22	4/10/23	4/16/24